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SUMMARY
Considering the epidemic situation of gambiense human African trypanosomiasis (HAT) at the end of the twentieth
century, the World Health Organization (WHO) and partners strengthened disease control and surveillance. Over the last
15 years, the activities implemented through the National Control Programmes have brought gambiense HAT under
control and now its elimination is deemed as an achievable goal. In 2012, WHO targeted gambiense HAT for elimination as
a public health problem by 2020. The ﬁnal goal will be the sustainable disease elimination by 2030, deﬁned as the
interruption of the transmission of gambiense HAT. The elimination is considered feasible, because of the epidemiological
vulnerability of the disease, the current state of control, the availability of strategies and tools and international commitment
and political will. Integration of activities in the health system is needed to ensure the sustainability of the elimination. The
development of user-friendly diagnostic and treatment tools will facilitate the integration process. Adequate funding is
needed to implement activities, but also to support research that will make the elimination sustainable. A long-term
commitment by donors is needed and ownership of the process by endemic countries is critical.
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BACKGROUND
Human African trypanosomiasis (HAT), or sleeping
sickness, is a disease caused by extracellular protozoa
belonging to the genus Trypanosoma, which are
transmitted by the bite of an infected tsetse ﬂy
(genus: Glossina). The disease is endemic in 36
countries in sub-Saharan Africa, with about 70
million people living at risk of infection (Simarro
et al. 2012). HAT is considered as a neglected tropical
disease (NTD) (World Health Organization, 2012a)
and it aﬄicts mainly neglected populations in rural
areas where suitable environmental conditions for the
occurrence of the tsetse vector are present.
There exist two human pathogen subspecies
(i.e. Trypanosoma brucei gambiense and Trypanosoma
brucei rhodesiense), which are morphologically indis-
tinguishable. Western and central sub-Saharan
Africa are aﬀected by T. b. gambiense, which leads
to a chronic disease that may last for years (gambiense
HAT) (Checchi et al. 2008). This form of HAT
currently accounts for more than 95% of the total
cases. In eastern and southern AfricaT. b. rhodesiense
causes an acute disease that may be fatal within weeks
or months (rhodesiense HAT) (World Health
Organization, 1998; Brun et al. 2010).
After inoculation, the parasite is initially found in
the lymphatic system and bloodstream (haemolym-
phatic stage) but after a period of variable duration,
trypanosomes cross the blood–brain barrier and enter
the central nervous system (meningoencephalic
stage) causing a progressive neurological breakdown.
If untreated, patients progress to coma, severe organ
failure, and eventually death (Kennedy, 2008).
HISTORICAL PROGRESS , SITUATION DURING THE
PAST DECADE AND CURRENT EPIDEMIOLOGICAL
STATUS OF THE DISEASE
After the epidemics that took place at the beginning
of the 20th century, which killed an estimated 300000
and 500000 people in the Congo Basin and the
Busoga focus, respectively (Hide, 1999; Steverding,
2008), it appeared that HAT had been progressively
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controlled during the mid-50s. The annual number
of new declared cases decreased from more than
55000 (1940) to a minimum of 4435 (1964) (World
Health Organization, 2000). In the following decades
the rarity of the disease and competition from other
health priorities led to neglect of disease control and
surveillance. This allowed the number of new cases
to rise again to alarming levels at the end of the
twentieth century, reaching 37991 new cases declared
in 1998 (World Health Organization, 2006), with
an estimation of more than 300000 people infected
(World Health Organization, 1998). In addition,
social instability in some endemic countries and the
scarcity of funds contributed to hampering disease
control.
To face this epidemic situation, the World Health
Organization (WHO) and partners implemented a
series of initiatives aimed at bringing HAT back
under control. In 2001, pharmaceutical companies
producing medicines against HAT (Aventis (cur-
rently Sanoﬁ) and Bayer) agreed to provide these free
of charge to aﬀected countries through the WHO. In
addition, resources were made available for strength-
ening disease control and surveillance through the
support of the WHO to Sleeping Sickness National
Control Programmes (SSNCP). At the same time,
bilateral cooperation (Belgium, France) and non-
governmental organizations (NGOs) joined the eﬀort
and contributed to reversing the upward trend in the
number of HAT cases (Simarro et al. 2011). These
enhanced control activities resulted in an improved
epidemiological knowledge of the disease, as well as
in a sustained decrease in the number of reported
cases. By 2009, the number of reported new cases had
fallen below 10000, with fewer than 8000 in 2010,
2011 and 2012, and an estimated number of infec-
tions at around 20000 (World Health Organization,
2013c).
Recent trends in new HAT cases (Fig. 1) are
promising, but ﬁgures should be interpreted with
care: the disease occurs mainly in remote rural areas
where health infrastructures are weak. Cases are not
always recognized, which results in signiﬁcant under-
detection and under-reporting. Under-detection
and under-reporting are diﬃcult to estimate, but
some available data suggest that 50–65% of cases are
currently not reported (Mumba et al. 2011; Simarro
et al. 2013a). In particular, some of the areas
concerned by this problem are hard to reach because
of insecurity or diﬃcult terrain.
Fig. 1. Number of gambiense HAT new cases reported (1990–2012) and key events on the road to the elimination.
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It has been estimated that 70 million people live at
diﬀerent levels of risk of HAT infection. 57 million
(81%) are at risk of gambiense HAT, and this
population is distributed over an area of approxi-
mately 1·38 million km2 in 14 of the 24 countries
listed as endemic for gambiense HAT. More than
2 million people live in areas classiﬁed as high to very
high risk of gambiense HAT (Simarro et al. 2012).
The distribution of the disease, the population and
areas at risk and the level of control activities are
shown in Table 1.
The number of new reported cases of gambiense
HAT has been below 10000 since 2009, with 7106
cases declared in 2012. As of 2008, gambiense HAT
cases represent 98% of the total HAT cases and cases
of rhodesiense HAT accounting for the remaining
2%. In the last 5 years (2008–2012), 78% of gambiense
HAT cases were reported from the Democratic
Republic of the Congo (DRC), followed by Central
African Republic (8%), South Sudan (4%), Chad
(3·5%) and Angola (3%) (Table 1) (World Health
Organization, 2012b).
Currently, SSNCP are functional in 15 endemic
countries (Angola, Benin, Burkina Faso, Cameroon,
Central African Republic, Chad, Congo, Côte
d’Ivoire, the DRC, Equatorial Guinea, Gabon,
Guinea,Mali, Uganda andTogo). All these countries
have a functioning surveillance system for gambiense
HAT. In Ghana, Nigeria and South Sudan there is
not a structured SSNCP but there is a surveillance
system run by diﬀerent structures of the Ministry of
Health. In Gambia, Guinea Bissau, Liberia, Niger,
Senegal and Sierra Leone, SSNCP do not exist, and
no surveillance activities are performed. Field assess-
ments of the epidemiological situation have been
carried out in Senegal and Sierra Leone (Table 1).
EPIDEMIOLOGICAL CHARACTERISTICS OF
DIFFERENT FOCI OF GAMBIENSE HAT
HAThas a patchy geographical distribution, which is
restricted to circumscribed areas (foci) (Welburn and
Maudlin 2012). This distributional pattern is caused
by a complex set of factors involving interactions
between the environment, the host, the vector and the
parasite. These complex relationships are not always
fully understood. The foci of the disease have been
fairly stable over time. The focus was qualitatively
deﬁned by the WHO Expert Committee in 1986
as ‘a zone of transmission to which a geographical
name is given (locality, region or river)’ (World
Health Organization, 1986). This deﬁnition is useful
to allocate resources, to plan control activities, to
measure the burden of the disease and to monitor the
evolution of the epidemiological situation. Currently,
303 foci of gambiense HAT are identiﬁed (Table 1)
(World Health Organization, 2012b).
Analysing the epidemiological patterns of these
foci, it is possible to distinguish three diﬀerent
situations. The three epidemiological settings can
be characterized on the basis of the reported intensity
of disease transmission (Simarro et al. 2012, 2013a):
1. Foci at high to very high intensity of transmission.
These are deﬁned as those where the average
annual number of cases reported is at least 1 per
1000 inhabitants.
2. Foci at moderate intensity of transmission. They
are those where at least 1 case per 10000
inhabitants (but less than 1 per 1000 inhabitants)
has been reported yearly.
3. Foci at low to very low intensity of transmission.
They are those where at least 1 case per 1000000
inhabitants per annum (but less than 1 case per
10000 inhabitants) has been observed.
The average annual number of reported cases can be
calculated for diﬀerent time periods. In previous
studies, a 10-year study period was used. However, a
shorter time period (i.e. 5 years) might be more
appropriate to follow the evolution of the epidemio-
logical situation.
There are still a few areas where transmission
intensity is not well known, and which require
further investigation. Among these areas we dis-
tinguish two diﬀerent situations:
1. Foci where disease transmission is known to be
taking place (cases are present), but which are
characterized by diﬃcult access because of terrain
or security constraints. As surveillance in these
areas has been hampered, the intensity of trans-
mission needs to be better assessed.
2. Foci which have not reported cases in the last
decades but which do not have an eﬀective
surveillance system in place. These areas have a
history of disease transmission, and for most of
them the current ecological characteristics still
make it possible. The absence of reported cases
over a long period of time makes the absence of
transmission probable. Investigations are needed
to ascertain the presence or absence of trans-
mission.
THE CASE OF RHODESIENSE HAT
Rhodesiense HAT has to be considered as a zoonosis
with occasional presence in human beings. Its current
epidemiology is characterized by a low level of
endemicity with sporadic human cases. However,
epidemics can occur. They have been linked to
environmental changes or major social disruptions
(Morris, 1959; Fèvre et al. 2001; Jelinek et al. 2002;
Kaare et al. 2007), which have resulted in changes in
population distribution and large-scale movements
of livestock and people to marginal areas more
exposed to infected tsetse ﬂies. As opposed to
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Table 1. Gambiense HAT endemic countries (cases reported, area and population at risk, number of foci, surveillance and control activities)
Country
No. of cases
Area at risk
(km2×102)
(% of total
country area)
Pop. at risk
(no. people×103)
(% of total country
population)
No. of foci
described
Activities of surveillance and control
2003–2007 2008–2012 SSNCP Active screening Passive screening Vector control Surveillance
Angola 8875 1206 2253 (18%) 5864 (46%) 46 Yes Yes Yes Sporadic Yes
Benin 0 0 – – 3 Yes No Integrated No Yes
Burkina Faso 0 0 – – 5 Yes Sporadic Yes Yes Yes
Cameroon 75 75 173 (4%) 631 (3%) 12 Yes Yes Yes Sporadic Yes
Central African
Republic
3057 3156 658 (10%) 433 (10%) 8 Yes Yes Yes No Yes
Chad 1268 1411 142 (1%) 465 (5%) 4 Yes Yes Yes Sporadic Yes
Congo 2477 456 1150 (34%) 2566 (64%) 19 Yes Yes Yes No Yes
Côte d’Ivoire 226 49 286 (9%) 2672 (13%) 15 Yes Yes Yes Sporadic Yes
Democratic
Republic of the
Congo
48304 31716 7894 (34%) 36242 (53%) 118 Yes Yes Yes Sporadic Yes
Equatorial Guinea 90 29 65 (24%) 43 (7%) 4 Yes Yes Yes Sporadic Yes
Gabon 189 86 167 (6%) 803 (53%) 8 Yes Yes Yes Sporadic Yes
Gambia 0 0 – – 1 No No No No No
Ghana 0 0 – – 1 No No Yes Yes Yes
Guinea 436 364 184 (8%) 2606 (26%) 13 Yes Yes Yes Yes Yes
Guinea Bissau 0 0 – – 3 No No No No No
Liberia 0 0 – – 4 No No No No No
Mali 0 0 – – 6 Yes No Yes Yes Yes
Niger 0 0 – – 1 No No No No No
Nigeria 65 7 70 (1%) 2183 (2%) 4 No Sporadic No Sporadic Yes
Senegal 0 0 – – 5 No No No No Field
assessment
Sierra Leone 0 0 18 (3%) 170 (3%) 5 No No No No Field
assessment
South Sudan 7914 1785 1001 (16%) 1270 (18%) 9 No Sporadic Yes No Yes
Uganda 1616 459 176 (9%) 2131 (7%) 7 Yes Yes Yes Sporadic Yes
Togo 0 0 – – 2 Yes No Integrated No Yes
Total 74592 40799 14239 (10%) 58080 (13%) 303
SSNCP: Sleeping Sickness National Control Programme.
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gambiense HAT, the possibility of importation of
rhodesiense HAT into new areas is not negligible
(Fèvre et al. 2004). The non-human reservoir is a key
element in the transmission cycle of rhodesiense
HAT (Hide et al. 1996), and the control of the disease
requires a multisectoral approach where animal
health and natural resources management (national
parks and game reserves) have an important role to
play (Selby et al. 2013).
Therefore, being a zoonosis with an important
animal reservoir, the elimination of rhodesienseHAT
as the total interruption of transmission of the disease
is considered not to be feasible and for this reason has
not been included in this analysis. However, the
possibility of its elimination has been considered as a
public health problem (World Health Organization,
2012a).
KEY EVENTS AND DECLARATIONS ON THE ROAD
TOWARDS ELIMINATION OF GAMBIENSE HAT
Over the last 15 years, the success in bringing
gambiense HAT from an epidemic situation to
control has been accompanied by a number of
political and technical declarations. The commitment
from partners has also contributed to bring about a
situation where the elimination of gambiense HAT is
now considered as a reachable goal (Fig. 1). Along the
way, key milestones have included:
In 1997, concerned by the worrying epidemiolo-
gical situation of HAT, the 50th World Health
Assembly (WHA) urged all member states in
endemic areas to reinforce control and surveillance
activities and coordinate their actions through the
Programme Against African Trypanosomiasis –
PAAT (a joint initiative of the Food and
Agriculture Organization of the United
Nations – FAO, the International Atomic Energy
Agency – IAEA, the WHO and the African
Union – Interafrican Bureau of Animal
Resources – AU/IBAR)) and emphasized the
need for resources to expand the control and
surveillance of the disease (World Health
Organization, 1997).
In 2000, during the summit held in Lomé
(Togo), the heads of states and governments
of African countries, considering the severe
impact of tsetse-transmitted trypanosomiasis on
the socio-economic development, expressed their
political will to embark on a continental cam-
paign of eradication, and consequently the African
Union (AU) established the Pan African Tsetse
and Trypanosomiasis Eradication Campaign
(PATTEC).
In 2001, two manufacturers of medicines against
HAT, Aventis and Bayer, committed to ensuring
production of the disease-speciﬁc drugs and to
donating the drugs to the WHO for free distri-
bution. An agreement was signed between Aventis
and WHO aimed at providing the WHO with the
ﬁnancial support to face the worrying situation of
gambiense HAT.
In 2003, the 56th WHA welcomed and supported
the PATTEC initiative and commended the eﬀorts
of the WHO to implement a programme for the
elimination of African trypanosomiasis as a public
health problem (World Health Organization,
2003).
In 2004, the 57th WHA Assembly urged member
states ‘to continue to give high priority to the
control of HAT’ and requested the WHO to reﬁne
control strategies and to promote an integrated
approach with the sectors and agencies concerned
(World Health Organization, 2004).
In 2005, the goal of elimination of HAT was
endorsed by the 55th WHO Regional Committee
for Africa and by the International Scientiﬁc
Council for Trypanosomiasis Research and
Control (ISCTRC).
In 2006 the agreement between WHO and Sanoﬁ-
Aventis (previously Aventis) was renewed. The
goal was to consolidate the control of the disease,
preparing the conditions for elimination and to
replace melarsoprol as the ﬁrst-line treatment for
the second stage of gambiense HAT.
In 2007, representatives of countries in which
HAT is endemic gathered in Geneva (Switzerland)
to discuss the elimination of HAT as a public
health problem. They concluded that the elimin-
ation of gambiense HAT was feasible (World
Health Organization, 2012b).
In 2011, the WHO – Sanoﬁ (previously Sanoﬁ-
Aventis) agreement was renewed with the goal of
implementing strategies to achieve and sustain
disease elimination through innovative strategies.
In the same year, the WHO’s Strategic and
Technical Advisory Group for NTDs (WHO
NTD STAG) deemed elimination to be techni-
cally feasible and HAT was included in the WHO
Roadmap on NTDs, which was launched in early
January 2012 with the target date for elimination as
a public health problem set by 2020 (World Health
Organization, 2012b).
In January 2012 a number of stakeholders includ-
ing pharmaceutical companies, donors and some
NGOs committed to the largest coordinated eﬀort
against NTDs through the London Declaration
(WorldHealthOrganization, 2013a). The declaration
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supports the WHORoadmap on NTDs to sustain,
expand and extend programmes to eliminate,
among other NTDs, HAT by 2020.
In December 2012, WHO convened a meeting
of SSNCPs focal points, experts from WHO
collaborating centres and members of the WHO
STAGNTD inGeneva. Elimination of gambiense
HAT was endorsed by SSNCPs of disease-
endemic countries. Strategies, tools and criteria
for the process of eliminating gambiense HAT
were laid out.
InApril 2013, theWHOExpertCommittee onHAT
control and surveillancemet inGeneva after 18 years,
to discuss the current epidemiological patterns
of the disease, the new diagnostic approaches and
the new therapeutic regimens. Final recommenda-
tions to achieve disease elimination were addressed
(World Health Organization, 2013c).
CONCEPT OF ELIMINATION OF HAT
The WHO Roadmap on NTDs included HAT with
the target date for elimination as a public health
problem by 2020, deﬁned as the reduction of HAT
incidence to fewer than 1 new case per 10000
population in at least 90% of foci and to fewer
than 2000 cases reported globally (World Health
Organization, 2012a). The disease-endemic coun-
tries and experts from WHO collaborating centres
considered this target as an advanced level of control
only and as an intermediate objective in the way to
reach the ﬁnal goal of sustainable HAT elimination
by 2030. This last goal was deﬁned following the
WHO NTD STAG recommendation as the inter-
ruption of the transmission of gambiense HAT (zero
disease incidence) in a condition where continued
actions to prevent re-emergence of the diseases may
be required (World Health Organization, 2012b).
FEASIBILITY OF ELIMINATION OF GAMBIENSE
HAT
In 1989, the International Task Force for Disease
Eradication (ITFDE) set out criteria for assessing
potential eradication or elimination of diseases
or conditions (Centers for Disease Control and
Prevention, 1993), some related to the technical
feasibility (epidemiological vulnerability, availability
of eﬀective and practical interventions or demon-
strated feasibility of elimination) and others related to
the political will or popular support as the perceived
burden of the disease.
Epidemiological vulnerability
Gambiense HAT does not spread easily and humans
are the only signiﬁcant reservoir. Animal hosts have
been described but more data are needed to elucidate
their role as a reservoir in the transmission cycle.
Such a role does not seem to be major (Funk et al.
2013).
The geographic distribution of the disease is well
known and limited to 24 endemic countries. Besides,
97% of the cases are declared in just 5 countries, with
approximately 80% of all the cases being reported
from the DRC (Simarro et al. 2013a). In addition,
in countries where gambiense HAT is endemic,
only 10% of the national area is aﬀected by the
transmission of the disease (Simarro et al. 2012).
A comprehensive database (WHO Atlas of HAT)
compiles geo-referenced data which enable mapping
at the village level, cases and screening activities
reported from 2000 (Simarro et al. 2010).
Eﬀective, practical intervention tools available
There is no vaccine against trypanosomiasis, and one
will not become available in the coming years.
However, eﬀective tools for screening and treatment
are available, although they are not easy to im-
plement. Also, control tools are not appropriate
for the involvement of ﬁxed facilities of the health
system in control and surveillance. Nevertheless,
these tools have proven eﬀective in reducing preva-
lence. The production and quality of speciﬁc
medicines is guaranteed and they are aﬀordable as
they are generously donated at no cost by manufac-
turers. Availability is ensured by an eﬀective distri-
bution systemmanaged by theWHO in collaboration
with MSF-Logistique.
Integration of treatment and diagnosis in the
health system is of the essence to spread the activities
in time and space and ensure sustainability. Cheaper
and user-friendlier diagnosis and treatment tools
will make integration easier. There are currently new
promising screening (Buscher et al. 2013) and
treatment tools (Torreele et al. 2010; Jacobs et al.
2011) in the pipeline, which could facilitate the
involvement of the health system.
Complete elimination of the vector does not
seem feasible (World Health Organization, 1998;
Molyneux, 2001; Hargrove, 2002). Nevertheless,
new tools for vector control are being introduced,
which are cheaper and easier to use (Esterhuizen et al.
2011). They have a role to play in supporting targeted
interventions in particular transmission areas, where
vector control will synergize with medical ap-
proaches.
Demonstrated feasibility of elimination
As a proof of principle, elimination has been achieved
previously in some foci (Bruto da Costa et al. 1916;
Simarro et al. 2006) and a strong reduction of the
disease was reached at the continental level in the past
753Towards elimination of gambiense human African trypanosomiasis
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0031182013002102
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 09:57:07, subject to the Cambridge Core terms of use, available at
with tools that have lower performance levels than
those available today (Simarro et al. 2008; Welburn
et al. 2009). Technical feasibility was acknowledged
by SSNCPs during a meeting held in Geneva in
December 2012 (WorldHealthOrganization, 2012b).
Political will
Political commitment to ﬁght the disease was
expressed by the heads of state and government of
African countries through an oﬃcial declaration
issued from the summit of the OAU held in Lomé
in 2000 (Organization of African Unity, 2001). In
addition, WHO member states committed to HAT
elimination by endorsing the WHO Road Map on
NTD during the 66th WHA held in Geneva in May
2013 (World Health Organization, 2012a, 2013b).
The international community showed their commit-
ment to HAT elimination through the London
Declaration in January 2012 (World Health
Organization, 2013c).
Perceived burden of the disease
The disease has a case fatality rate that is close to
100%. In endemic areas, people fear infection because
of the suﬀering, lethality and the risk of stigma it
entails. Aﬀecting mainly individuals of productive
age, and being a chronic disease, a case of gambiense
HAT in a family unit causes important economic
losses, as measured in terms of decreased income and
increased expenditure (Lutumba et al. 2007).
STRATEGIES FOR ELIMINATION OF GAMBIENSE
HAT
In the case of gambiense HAT, three classical control
methods have been described and used for almost
100 years:
1. Active case-ﬁnding by mobile teams, which
perform a serological screening in large popula-
tions (villages, neighbourhoods or other popu-
lation settlements) and subsequently seek
parasitological conﬁrmation of serological sus-
pects. Active case detection may determine a
substantial reduction in disease prevalence,
mainly when applied in successive rounds
(Robays et al. 2004; Simarro et al. 2006; Checchi
et al. 2012). Low participation rates of at-risk
populations have been described under certain
circumstances mainly when screenings are period-
ically repeated, prevalence is lowering, and the
impact of the active case ﬁnding is decreasing
(Robays et al. 2004; Welburn et al. 2009). Active
case ﬁnding always has to include adequate
treatment of all detected cases.
2. Passive case-ﬁnding and adequate treatment by
ﬁxed health facilities. This method concerns
patients seeking healthcare with signs or symp-
toms suggestive of HAT infection. Serological
tests are used for initial screening, followed by
tests for parasitological conﬁrmation in serological
suspects. The introduction of individual and
simple serological tests (lateral ﬂow formats)
(Buscher et al. 2013) can facilitate passive screen-
ing in sites where staﬀ are not highly skilled in
HAT-related techniques. Cases should always be
adequately treated after detection.
3. Vector control to reduce the tsetse population,
using the diﬀerent methods available according
to the characteristics of the diﬀerent foci (World
Health Organization, 2013c).
To combat the disease it is necessary to combine
these three methods as appropriate. In the diﬀerent
epidemiological situations, diﬀerent combinations
and ‘dosage’ of each method has to be deployed,
based on:
– Intensity of transmission;
– Precise understanding of the epidemiological
setting, including geographic and demographic
data;
– Accessibility and capabilities of the existing health
facilities; and
– Knowledge of vector ecology, including the
patterns of human–vector contact, the sites where
vector control must be applied and the methods to
be utilized.
Control and elimination strategies deﬁned according
to the intensity of transmission and epidemiological
settings have to be ﬂexible and dynamic enough to be
adapted to the changing disease patterns and capa-
cities of the local health services (Simarro et al.
2013a).
IMPLEMENTATION OF CONTROL AND
SURVEILLANCE ACTIVITIES ACCORDING TO THE
EPIDEMIOLOGICAL STATUS OF EACH VILLAGE
Considering that HAT is a focal disease, the focus
and its level of transmission is the epidemiological
unit and disease elimination strategies must be
planned and monitored at the focus rather than the
country level. At the same time, ﬁeld interventions
are to be planned and implemented at the village
level, according to its speciﬁc epidemiological status.
Villages in each focus can be categorized according
to the presence of cases in the previous years:
Villages which have reported cases in the previous
3 years.
Villages which have reported cases in the previous
5 years, but not in the previous three.
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Villages which have reported no cases in the
previous 5 years.
Control and surveillance activities therefore will be
planned according to this village-level categorization
within a focus (Fig. 2). The classiﬁcation of villages is
updated yearly. To this end, diagnosed cases have to
be carefully reported, including the possible village
where the transmission took place.
Active screening
Active screening plays an important role in foci where
transmission is high or very high. The active case-
ﬁnding through mobile teams will be done yearly in
all the villages which have presented cases in the
previous 3 years. In the villages which have reported
cases in the previous 5 years, but not in the previous
3, an active screening will be performed every 3 years.
In foci at moderate, low and very low intensity of
transmission it is expected that the number of villages
presenting cases will be low, and therefore the volume
of active screening will be limited. The Card
Agglutination Test for Trypanosomiasis (CATT) is
the main tool used for active screening.
If a serological suspect detected in a sentinel centre
is conﬁrmed by parasitological examinations, a
reactive active case-ﬁnding survey will be carried
out for 3 consecutive years in the area of activity of the
newly detected case. In some foci, the skills of the
local health staﬀ to perform the parasitological tests
and an active screening could have been lost; in those
cases, support from national or regional institutions
can be requested in order to carry out the active
screening and to build the local capacity.
Passive screening
Passive screening has to be performed in the selected
health structures located within the focus (sentinel
sites). The sentinel sites will be selected according to
their capacities, the population covered and the
frequenting by the population at risk. The perform-
ance of the passive detection could be increased by
healthcare workers in health posts, who could detect
the signs and symptoms evoking HAT infection and
then refer clinical suspects to the sentinel sites.
Passive screening is themost important component
for gambiense HAT control and surveillance in foci
with low and very low intensity of transmission,
where infection is rare and active case detection has
poor cost-eﬀectiveness. Passive screening is also a key
element in high, very high and moderate trans-
mission foci, as eﬀectiveness of active screening is
limited because of incomplete attendance at screening
sessions, inherent limitations of screening tools and
the lag between successive surveys.
If serological positive cases are detected by sentinel
sites among clinical suspects through individual
screening tests (also erroneously called rapid diag-
nostic tests – RDT), parasitological tests have to be
carried out to conﬁrm the diagnosis. If the serological
Fig. 2. Algorithm of interventions according to the epidemiological status of the villages in each focus.
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suspicion is not conﬁrmed, in particular epidemiolo-
gical settings samples could be sent to a WHO
collaborating centre for a more speciﬁc test (i.e.
immune trypanolysis) for conﬁrming the presence of
anti-trypanosomal antibodies (Van Meirvenne et al.
1995; Jamonneau et al. 2010).
When staﬀ at the peripheral level are not familiar
with parasitological tests for conﬁrmation, serological
suspects could be referred for parasitological tests to
health structures able to perform them or request
support from national or regional referral centres.
Vector control
Vector control is an eﬃcient tool to reduce tsetse ﬂies
numbers and therefore to reduce HAT transmission
(Solano et al. 2013). Vector control is applied
according to medical results in selected sites. It
could play an important role in high-prevalence foci
to help reduce transmission quickly, or in foci where
the intensity of transmission does not decrease after
repeated active screening rounds. It is not a priority
in foci with low or very low intensity transmission,
where it is only applicable if the intensity of
transmission is not reduced after repeated active
screening rounds.
There are a variety of tools for tsetse control and
the choice of the most suitable will depend on local
conditions (World Health Organization, 2013c).
MONITORING AND EVALUATING GAMBIENSE HAT
ELIMINATION. CERTIFICATION AND
VALIDATION OF ELIMINATION
Continuous monitoring and evaluation of the HAT
elimination process is needed to adapt the strategies
to the epidemiological situation and to assess the
results obtained. It will assure the sustainability of
the elimination and will prevent the re-emergence of
the disease.
The monitoring and evaluation of progress toward
elimination has to be based on data collected by
mobile teams and sentinel sites. Standard surveys
based on sampling approaches are not appropriate for
monitoring and evaluating trypanosomiasis elimin-
ation as they do not have suﬃcient statistical power
for decision-making due to the low prevalence of the
disease. The xenomonitoring of HAT infection in
vectors could contribute to monitoring the elimin-
ation of sleeping sickness by assessing the presence or
absence of parasites circulating in the vector.
However it is not currently applicable since tests for
molecular detection of T. b. gambiense infections in
tsetse ﬂies need to improve their sensitivity and
speciﬁcity if reliable results are to be obtained. In
addition, the low prevalence of infection in tsetse ﬂies
will require large-scale capture of ﬂies and to develop
protocols for pooling samples.
HAT will be considered eliminated in those foci
where after adequate surveillance is in place, no cases
are detected in all villages during a 5-year period. The
country will have to submit to the WHO a technical
report about the elimination of the focus and request
external evaluation by an international validation
group (IVG). The validation system has to be able
to ascertain the accessibility, coverage and quality
of the surveillance activities to verify the absence of
transmission and therefore to validate the elimin-
ation. The IVG will submit to the WHO a report
with the appropriate recommendations concern-
ing HAT elimination in the assessed focus. If the
IVG evaluation is positive, the WHO will endorse
elimination in the focus; otherwise, the WHO
will recommend corrective measures and the way
forward.
Even after a positive evaluation from the IVG, the
surveillance system has to be maintained in sentinel
sites to continuemonitoring and evaluating the focus.
Staﬀ working in primary healthcare centres and staﬀ
in sentinel sites will receive regular refresher training
to recognize the signs and symptoms suggestive
of gambiense HAT, and to maintain awareness of
the disease. The duration of this surveillance and
preparedness for response has yet to be determined
(World Health Organization, 2012b).
INDICATORS AND MILESTONES
In the framework of HAT elimination, the initial aim
is the reduction of HAT incidence to fewer than
1 case per 10000 inhabitants in at least 90% of
endemic areas, and to fewer than 2000 new cases
reported globally by 2020 (Maurice, 2013). The ﬁnal
aim is elimination as deﬁned by a reduction of HAT
incidence to no new cases from any foci by 2030
(World Health Organization, 2012b).
The progress towards elimination will bemeasured
by two primary quantitative indicators that will be
updated annually:
1. The number of new cases of HAT reported.
2. The number of foci validated as eliminated.
Two secondary sets of indicators are proposed to
assess the quality of the primary indicators and the
scope of the elimination activities.
1. Proportion of the population at risk covered by
control and surveillance activities (including
active and passive screening) (Simarro et al.
2013b). This indicator will be updated yearly.
2. Geographical extent of the infection and popu-
lation at diﬀerent levels of risk, as measured with
a previously described method (Simarro et al.
2012). This indicator will be calculated every
2 years.
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The milestones deﬁned for HAT in the WHO
Roadmap on NTDs and agreed by the SSNCPs are
shown in Table 2.
ROADBLOCKS TO BE OVERCOME AND RESEARCH
GAPS AND TOOLS NEEDED
On the road to eliminate HAT there exist important
challenges that need to be overcome. These chal-
lenges need to be addressed if gambiense HAT
elimination is to be achieved. They can be classiﬁed in
diﬀerent groups:
Epidemiological knowledge of the disease
Knowledge gaps in geographical distribution. Grey
areas are still present, where epidemiological knowl-
edge is limited. These are found mainly in old foci
without appropriate surveillance, and in regions
characterized by diﬃcult accessibility, or aﬀected by
security constraints. The epidemiological situation in
these areas needs to be clariﬁed. Adapted and
adequate sensitive tools will help to assess these
areas and to ﬁll the mapping gaps.
Epidemiological role of asymptomatic, seropositive
human carriers with undetectable parasitaemia. The
presence of seropositive/aparasitaemic human cases
and healthy carriers is well described in gambiense
HAT (Bucheton et al. 2011; Jamonneau et al. 2012).
They could play a role in the persistence of disease
transmission. Further studies are needed to clarify
their epidemiological signiﬁcance, and to develop
appropriate strategies for their management.
Epidemiological role of animals as reservoir of gam-
biense HAT. The presence of T. b. gambiense in
animals has been widely described (Duke, 1931;
Makumyaviri et al. 1989; Njiokou et al. 2006, 2010;
Cordon-Obras et al. 2009). The role they can play as
reservoirs to maintain the transmission of gambiense
HAT needs to be elucidated.
Underdetection and underreporting. Gambiense
HAT is a rural disease, occurring in remote areas
not always fully accessible for the health system.
Under-detection and under-reporting are a reality,
and they have been estimated in diﬀerent ways.
Additional indicators and modelling tools for esti-
mating the location and abundance of undetected
cases have to be developed.
Risk of reintroduction of the infection after elimination
from a focus. A risk of reintroduction of HAT after
elimination exists, and it requires maintenance of
surveillance activities after HAT has been eliminated
from a focus. Studies on the risk factors of HAT
reintroduction are encouraged, with a view to
ensuring sustainability of elimination.
Integration of control and surveillance into existing
health systems. Health systems in gambiense HAT
endemic areas are often characterized by low attend-
ance rates at healthcare facilities, lack of preparedness
of staﬀ and sometimes staﬀ overloading. Operational
research is needed to improve the integration of
control and surveillance of gambiense HAT into the
existing health systems.
Lack of skills of health staﬀ on gambiense HAT control
and surveillance. Experienced and committed staﬀ
presently involved in HAT control and surveillance
are progressively retiring, and perspectives for
appropriate replacement are limited. Approaches to
engage a new generation of health staﬀ on gambiense
HAT elimination need to be implemented.
Lack of awareness among people at risk. When the
disease becomes rare, local knowledge of the disease
among the aﬀected populations is progressively lost.
Campaigns and tools to maintain awareness of
gambiense HAT among the populations in endemic
areas have to be developed and implemented.
Xenomonitoring for assessing gambiense HAT elimin-
ation. The feasibility of monitoring T. b. gambiense
infections in vectors should be further explored as a
potential tool for assessing HAT elimination pro-
grammes.
Screening, diagnosis and staging
Simpler and ensured serological tests. The introduc-
tion of simple, individual serological tests can help
the integration of gambiense HAT control and
surveillance into the health system, which will be
critical to achieve the elimination goal. Individual
Table 2. Quantitative indicators for HAT elimination as public health problem, 2012–2020 (World Health
Organization, 2012b)
2012 2013 2014 2015 2016 2017 2018 2019 2020
Cases annually reported 6000 5500 5000 4500 4000 3500 3000 2500 <2000
Number of foci reporting fewer than 1 case
per 10000 inhabitants
10% 30% 40% 60% 80% >90%
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serological tests are already under evaluation for
gambiense HAT. The available screening tools
(CATT and individual screening tests) are based on
the same native antigen which has a ceiling in its
production. New screening tools using new recom-
binant antigens which are easier to produce are
needed.
Accurate and simpler parasitological conﬁrmation
tests. The current diagnostic tools to conﬁrm the
disease are complex and tedious, have a limited
sensitivity and they need skilled and experienced
staﬀ. More user-friendly diagnostic tests for conﬁ-
rmation are needed to spread the diagnostic capabili-
ties to the health services.
Less-invasive staging tests. The staging of HAT to
establish the appropriate treatment is based on the
analysis of CSF obtained from a lumbar puncture.
This is a painful and not risk-free procedure.
Development of tests on blood or urine for stage
determination are encouraged.
Treatment
New user-friendly treatments. The current thera-
peutic regimens are complex to apply, cumbersome
in their logistics for distribution, and characterized
by considerable safety concerns. Safe drugs – if
possible oral –which are easy to use and active against
both forms and both stages of the disease are
required.
Clinical trials. Clinical trials to develop new drugs
forHATare complex and long lasting. The reduction
in the number of patients as elimination progresses
will further complicate clinical trials. Eﬀorts to
facilitate clinical trials, always ensuring the safety of
the patients, have to be considered.
CONCLUSIONS
The elimination of gambiense HAT is feasible, as
a result of the epidemiological vulnerability of
the disease, the current state of disease control, the
availability of eﬀective strategies and tools, the
existence of international commitment and political
will. The available strategies and tools have to be
adapted to the diﬀerent epidemiological settings to
maximize cost-eﬀectiveness.
Basic and operational research is needed to address
knowledge gaps and to improve control tools. The
development of new diagnostic and treatment tools
will enhance control interventions and will facilitate
the integration of a sensitive surveillance into the
health systems. The strategies for elimination should
be monitored and evaluated to ensure their appro-
priateness and eﬀectiveness in an elimination
scenario, to identify optimal interventions, and to
establish the timing for switching from one strategy
to the next.
The successful control activities carried out over
the last 15 years have substantially reduced the
burden of disease. Donors tend to lose interest
when the burden of a disease is decreasing. To
eliminate gambiense HAT a long-term commitment
by donors is needed. Advocacy is needed to sensitize
donors on the importance of switching from a control
to an eliminationmindset. Adequate fundingmust be
made available not only to implement elimination
activities in the ﬁeld, but also to support research that
will make the elimination eﬀort sustainable.
Alongside the commitment of donors, ownership
of the objectives and process of elimination by
endemic countries is critical. Gambiense HAT
elimination has to be included in national health
plans to facilitate its prioritization and to maintain its
proﬁle against competing health priorities.
The integration of gambiense HAT control and
surveillance programmes in health systems is a major
challenge. In the rural areas where trypanosomiasis is
prevalent, the overall performance of peripheral
health systems is often weak and characterized by
unskilled staﬀ, low attendance and low coverage.
Therefore, the strengthening of health systems to
implement the activities included in the elimination
strategies is essential.
Political instability and insecurity are inescapable
challenges in an elimination programme. The suc-
cessful elimination of gambiense HAT requires a
turmoil-free socio-political context.
Past and current experiences show that HAT
elimination is diﬃcult and will require more eﬀort,
time, and money than initially anticipated. The
inherent risks of failure are oﬀset by the beneﬁts
that accrue from a successful elimination campaign.
An elimination campaign has the ability to inspire
dedication and sacriﬁce among health workers, and to
attract donors, both of which are needed to overcome
the hurdles to success (Hopkins, 2013).
Much progress has been made in the ﬁght against
gambiense HAT, but the ﬁnal line of the struggle is
not in sight just yet.
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